A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Clinical trial NCT03777579 · SUSPENDED

Trial details

NCT number: NCT03777579
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: SUSPENDED
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2018-12-21
Primary completion: 2019-12-30
Enrollment: 375

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.